×
Choose Speciality

EXPLORE!

LOGIN

By signing up or signing in to eMediNexus, you consent to eMediNexus collecting and using your personal data in accordance with our Privacy Policy. We are committed to safeguarding your information and ensuring the highest standards of data protection. Your trust and privacy are of utmost importance to us.

Another SGLT2 inhibitor approved for type 2 diabetes

  799 Views

eMediNexus    22 December 2017

Ertugliflozin, a SGLT2 inhibitor has been approved to improve glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise. It is to be administered orally in once-daily doses. Two dose strengths will be available: 5-mg and 15-mg tablets.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.